Montes de Oca Balderas, P
The median follow-up duration was 1 year (IQR: 0.52 years), with key findings including a median weight loss of 11.7 kg and a median BMI at the most recent follow-up of 31.2 kg/m 2 , reflecting a median reduction of 3.7 kg/m 2
Attach the specific documentation that addresses the denial reason: updated clinical notes, lab results, prior treatment history, or a prescriber letter of medical necessity that cites the payers own formulary criteria
Understanding Off-Label Medication Use Understanding Off-Label Medication Use Healthcare providers may prescribe FDA-approved medications for uses not listed in the official FDA-approved labeling
As a healthcare organization, we are committed to providing our patients with advanced, high-quality care close to home
The key difference: EVOKE+ allowed participants with cerebral small vessel disease